Mitchell Lawrence Jones - 11 Feb 2026 Form 4 Insider Report for PALISADE BIO, INC. (PALI)

Role
Chief Medical Officer
Signature
/s/ Ryker Willie, Attorney-in-Fact
Issuer symbol
PALI
Transactions as of
11 Feb 2026
Net transactions value
-$3,481
Form type
4
Filing time
13 Feb 2026, 20:10:12 UTC
Previous filing
11 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Jones Mitchell Lawrence Chief Medical Officer 1902 WRIGHT PLACE, SUITE 200., CARLSBAD /s/ Ryker Willie, Attorney-in-Fact 13 Feb 2026 0001993292

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PALI Common Stock Options Exercise +8,000 +110% 15,252 11 Feb 2026 Direct F1, F2
transaction PALI Common Stock Sale $3,481 -1,989 -13% $1.75 13,263 12 Feb 2026 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PALI Restricted Stock Units Options Exercise $0 -8,000 -33% $0.000000 16,000 11 Feb 2026 Common Stock 8,000 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs") granted on February 11, 2025.
F2 Includes 3,400 shares acquired under the Issuer's Employee Stock Purchase Plan on November 20, 2025.
F3 The sale reported in this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs.
F4 Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F5 The RSUs shall vest in three equal annual installments beginning on February 11, 2026, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.